基于肠激素的药理学:代谢疾病治疗的新型制剂与未来可能
本综述总结了基于肠激素的治疗进展,涵盖GLP-1受体激动剂(基于exendin-4和天然GLP-1,可每日或每周皮下注射或口服)、DPP-4抑制剂、小分子口服激动剂、促GLP-1分泌化合物,以及GLP-1/胰高血糖素和GLP-1/GIP双受体激动剂、GLP-1/GIP/胰高血糖素三受体激动剂在2型糖尿病和肥胖治疗中的未来展望。
要点
- GLP-1受体激动剂通过刺激胰岛素分泌、抑制胰高血糖素分泌降低血糖,并通过中枢作用诱导饱腹感减轻体重。
- DPP-4抑制剂通过防止GLP-1和GIP失活,延长餐后其升高水平,从而实现GLP-1受体激动效应。
- GLP-1/胰高血糖素和GLP-1/GIP双受体激动剂及GLP-1/GIP/胰高血糖素三受体激动剂通过作用于胰岛和外周组织改善β细胞功能、刺激能量消耗,具有降低血糖和体重的潜力。
核心结论
- 本综述总结了基于肠激素的治疗进展,并展望了其在2型糖尿病和肥胖中的应用前景。
研究设计与样本
- 综述,总结基于肠激素的疗法在2型糖尿病和肥胖治疗中的进展。
主要发现
- 临床上使用的GLP-1受体激动剂基于exendin-4和天然GLP-1,有每日或每周皮下注射或口服制剂。
- DPP-4抑制剂通过防止GLP-1和GIP失活,延长餐后其升高水平,实现GLP-1受体激动效应。
- 其他GLP-1受体激动相关进展包括小分子口服激动剂和具有药物性刺激肠道GLP-1分泌潜力的化合物。
- GLP-1/胰高血糖素和GLP-1/GIP双受体激动剂及GLP-1/GIP/胰高血糖素三受体激动剂通过作用于胰岛和外周组织,改善β细胞功能并刺激能量消耗,具有降低血糖和体重的潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to reduce glucose levels through stimulation of insulin secretion and inhibition of glucagon secretion. They also reduce body weight by inducing satiety through central actions. The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c. or oral administration. GLP-1 receptor agonism is also achieved by inhibitors of dipeptidyl peptidase-4 (DPP-4), which prevent the inactivation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their raised levels after meal ingestion. Other developments in GLP-1 receptor agonism include the formation of small orally available agonists and compounds with the potential to pharmaceutically stimulate GLP-1 secretion from the gut. In addition, GLP-1/glucagon and GLP-1/GIP dual receptor agonists and GLP-1/GIP/glucagon triple receptor agonists have shown the potential to reduce blood glucose levels and body weight through their effects on islets and peripheral tissues, improving beta cell function and stimulating energy expenditure. This review summarises developments in gut hormone-based therapies and presents the future outlook for their use in type 2 diabetes and obesity.
引用
- Tschöp M, Nogueiras R, Ahrén B, et al. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023. PMID: 37209227. doi:10.1007/s00125-023-05929-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。